FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.
MORE ON THIS TOPIC